What is Eucalyptus?
Founded in 2019 and headquartered in New South Wales, Eucalyptus operates as a direct-to-consumer health platform designed to bridge gaps in the traditional Australian healthcare system. By offering a private-pay alternative to government-subsidized care, the company provides streamlined access to medical consultations and treatments. Its business model is built upon the premise of patient-centric digital delivery, allowing the firm to capture significant market share among individuals seeking efficient, high-quality healthcare services outside of standard insurance or public health channels. The company's growth is characterized by its ability to scale operations while maintaining rigorous clinical standards.
How much funding has Eucalyptus raised?
Eucalyptus has raised a total of $112.3M across 3 funding rounds:
Series A
$30M
Series B
$22.3M
Series C
$60M
Series A (2021): $30M with participation from Blackbird
Series B (2021): $22.3M led by NewView Capital, W23, AirTree Ventures, and Blackbird Ventures
Series C (2022): $60M supported by BOND
Key Investors in Eucalyptus
BOND
BOND is a global technology investment firm that supports visionary founders throughout their entire life cycle of innovation and growth.
NewView Capital
NewView Capital is a venture growth firm that specializes in investing in high-potential enterprise software and fintech companies through primary and secondary investments.
AirTree Ventures
Airtree is an early-stage venture capital firm that supports Australian and New Zealand founders in building iconic technology companies.
What's next for Eucalyptus?
With the infusion of capital from its latest funding round, Eucalyptus is well-positioned to accelerate its expansion strategy. The company is expected to focus on deepening its service offerings and enhancing its digital infrastructure to support a broader range of medical specialties. As it moves beyond its initial scaling phase, the firm will likely prioritize operational efficiency and the integration of advanced healthtech tools to maintain its competitive edge. The continued support from high-profile venture capital firms suggests a strong outlook for the company as it seeks to redefine the patient experience in the Australian market and potentially explore further regional opportunities.
See full Eucalyptus company page
